Is Echo IQ (ASX:EIQ) a Buy? Mayo Clinic Deal and ASX Index Entry Signal a Major Turning Point

Echo IQ Gains on Mayo Deal and FDA Filing

Echo IQ (ASX: EIQ) surged 17% on Tuesday on the back of two catalysts arriving at once. The company has joined the Mayo Clinic Platform’s Solutions Studio program, providing access to Mayo’s own network and over 80 external partner hospitals, and the stock has been added to the ASX All Ordinaries Index. Despite trading at A$0.72, the share price still reflects an early-stage company with its biggest commercial trigger still ahead, which raises the key question for investors right now: Is this the moment to buy, or should you wait for FDA clearance before committing?

What are the Best ASX Healthcare Stocks to invest in right now?

Check our buy/sell tips

What the Mayo Clinic Deal Actually Means

This is not simply a validation stamp from a famous institution. The commercial agreement allows Echo IQ to offer EchoSolv HF through the Mayo Clinic Platform, creating a direct pathway into global clinical workflows across Mayo’s own network and more than 80 external partner hospitals. In a clinical study conducted at Mayo across more than 17,000 echocardiograms, the company’s EchoSolv HF software detected heart failure with 99.5% sensitivity. That result is what earned the commercial relationship, not just a research footnote.

Following that study, Echo IQ lodged its FDA 510(k) submission for EchoSolv HF in December 2025. With the application currently under formal review, clearance remains the single most significant catalyst for 2026, with the company guiding investors to expect a decision in the first half of the year. For investors, the Mayo deal is significant because it removes a critical question about market access. The distribution channel across Mayo’s network and 80+ external partner hospitals is contractually agreed and ready to activate the moment FDA clearance is granted. 

Two Products, One Platform, a US$60 Billion Market

Echo IQ already has one FDA-cleared product in the market. EchoSolv AS, which detects aortic stenosis, is deployed across 36 US cardiology networks through partners ScImage and MedAxiom. That existing footprint matters because it shows the commercial model is working, even before the larger heart failure product receives clearance.

The heart failure opportunity is where the real scale lies. Heart failure is the leading cause of rehospitalisation in the United States, accounting for approximately 17% of all US healthcare spending. The problem is that the current standard of care detects only around 50% of cases. EchoSolv HF, by comparison, achieved 99.5% sensitivity in the Mayo study. This is a meaningful clinical gap, and closing it has significant commercial implications for Echo IQ.

The company operates a per-scan revenue model, which means recurring income grows as the technology is used more widely across hospital networks. If FDA clearance comes through for EchoSolv HF in the first half of 2026, the revenue opportunity changes materially, given the scale of the heart failure problem.

Buy Now or Wait for FDA? The Investor’s Takeaway

The bull case rests on three things coming together. Entry into the Mayo Clinic Platform de-risks commercialisation with immediate access to 80+ external partner hospitals. Index inclusion brings a new wave of institutional buyers. And FDA clearance for EchoSolv HF, anticipated in the first half of 2026, is the re-rating event that could shift the stock significantly higher.

The bear case is straightforward. Echo IQ is pre-revenue on its main product. FDA decisions can be delayed beyond guidance, and healthcare adoption in the US tends to move slowly even after clearance is granted.

It is worth noting that Pro Medicus (ASX: PME) signed its own Mayo Clinic agreement in 2016 and never looked back. We are not suggesting EIQ is the next Pro Medicus, but the parallel is worth keeping in mind when thinking about what institutional hospital partnerships can mean for Australian healthtech companies.

We believe Echo IQ represents a speculative buy for risk-tolerant investors at current levels. The FDA clearance decision remains the real re-rating trigger, but investors waiting for confirmed clearance may find the move has already happened by then.